RedHill Biopharma Announced The Placement Of Low-dose Rifabutin-triple Therapy, Talicia, As An Empirically-prescribed First-line Option For Helicobacter Pylori Infection In The Newly Published American College Of Gastroenterology Clinical Guideline
RedHill Biopharma Announced The Placement Of Low-dose Rifabutin-triple Therapy, Talicia, As An Empirically-prescribed First-line Option For Helicobacter Pylori Infection In The Newly Published American College Of Gastroenterology Clinical Guideline
redhill biopharma宣佈將低劑量利奈唑胺聯合療法Talicia作爲根據經驗開具的幽門螺桿菌感染的一線選擇，納入新發布的美國消化病學會臨床指南
RedHill Biopharma Announced The Placement Of Low-dose Rifabutin-triple Therapy, Talicia, As An Empirically-prescribed First-line Option For Helicobacter Pylori Infection In The Newly Published American College Of Gastroenterology Clinical Guideline
RedHill Biopharma宣佈在新發布的美國胃腸病學會臨床指南中將低劑量利法布汀三聯療法塔利西亞作爲幽門螺桿菌感染的經驗處方第一線選擇
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間